VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2021 | Phase II study of lecanemab in early AD

Lecanemab is an investigational monoclonal antibody against amyloid beta protofibrils. Chad Swanson, PhD, Eisai, Inc., Woodcliff Lake, NJ, gives an overview of lecanemab (BAN2401) and discusses the main findings of the Phase II study (NCT01767311), evaluating its safety, tolerability, and efficacy in patients with early Alzheimer’s disease (AD). Lecanemab was well tolerated and showed a robust reduction in brain amyloid as measured by amyloid PET over 18 months of treatment. This reduction was accompanied by a decrease in clinical decline across a number of AD clinical assessments. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.

Disclosures

Dr Swanson is an employee of Eisai, Inc.